Need more? Try out  Advanced Search (20+ criteria)»

logo

Last Update

This profile was last updated on 8/31/2011 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Sophie Fosså?

Sophie D. Fosså

University of Oslo

HQ Phone:  +47 22 85 50 50

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

University of Oslo

Problemveien 7

Oslo, Oslo,0313

Norway

Web References(99 Total References)


The Lancet Conferences: Asia Medical Forum 2007 - Asia and cancer management in the 21st century

www.thelancetforum.com [cached]

Prof Sophie Fossa
Prof Sophie Fossa Senior Clinical Scientist/Consultant, Department of Clinical Research, Section for Outcome Research, The Norwegian Radium Hospital, Norway


Hormone Therapy :: Advanced Prostate Cancer from Malecare

advancedprostatecancer.net [cached]

According to Sophie Dorothea Fosså, MD, a professor in the department of oncology at Oslo University Hospital in Norway, "In these patients the combination of radiotherapy and hormones may be considered as a standard curative treatment option and patients should be informed about this.
She also said "This updated data showed that at 10 years, cumulative prostate-cancer-specific mortality was 8.3% in patients assigned combination treatment compared with 18.9% in the anti-androgen alone arm; at 15 years, it was 12.4% compared with 30.7% in the anti-androgen alone arm." In 2009, the Scandinavian Prostate Cancer Group presented results from this study showing a 12% reduction of prostate cancer specific mortality in patients on combined treatment after a median follow-up of 7.6 years. In these updated results, Fosså provided the 10-year and 15-year prostate-cancer-specific survival after a median observation of 10.7 years. "Of course the difference was less for the overall mortality though still significant," Fosså said. Fosså when she indicated that this method of combined therapy might provide a cure for prostate cancer.


www.valuebasedcancer.com

Lead investigator Sophie D. Fosså, MD, PhD, Professor and Senior Researcher, Department of Oncology, Oslo University Hospital, Norway, explained that the study was initiated in 1996, when the standard therapy for locally advanced or high-risk prostate cancer was lifelong hormonal therapy alone; it is still standard in Scandinavia.
"Lifelong therapy with antiandrogens improves survival," Dr Fosså said. At the time the study was initiated in 1996, prostate cancer that extended through the prostatic capsule was considered inoperable, she continued, and although surgical techniques have improved since then, surgery is not typically used in Scandinavia for these patients. "The combination of radiotherapy and hormone therapy more than doubled the 10-year and 15-year survival rate and confirms that this approach should be a standard curative option for men with this type of prostate cancer who have at least another 10-year life expectancy," Dr Fosså told listeners at a press cast. Updated, Long-Term Results The updated analysis was based on 11 years of observation of mortality data from the Norwegian and Swedish death registries. The 875 patients enrolled in the trial (aged Dr Fosså said. Looking at overall mortality, hormones plus radiation achieved superior results, but the gap between the 2 arms was narrower than for prostate cancer-specific mortality, because many patients died from other diseases, Dr Fosså added.


www.caringfortheages.com

Compared with antiandrogen therapy alone, the combination more than halved the 10- and 15-year rates of prostate cancer-specific mortality, lead author Dr. Sophie Dorothea Fosså reported in a press briefing preceding the 2014 Genitourinary Cancers Symposium sponsored by the American Society of Clinical Oncology.
In fact, the benefit increased with the duration of follow-up. "Given the high mortality reduction and, what is important, only 8% prostate cancer-specific mortality at 10 years, our conclusion is that this combination of radiotherapy and hormones may be considered as a standard curative treatment option in these patients," she commented. "And it is actually ... more or less comparable to a modern prostatectomy series." Approximately 30%-40% of the patients studied would likely undergo prostatectomy today, estimated Dr. Fosså, who is a professor in the department of oncology at Oslo University Hospital. Such patients were not considered surgical candidates in 1996, when the trial began, according to Dr. Fosså. All 875 patients received 3 months of medical castration therapy, consisting of leuprolide injection (Procren Depot) plus oral flutamide (Eulexin). Half then received lifelong antiandrogen therapy alone (oral flutamide), whereas the other half received that therapy plus initial radiation therapy consisting of 75 Gy to the prostate, "which, at that time, was a relatively high dose," she noted. Initial results, previously reported after a median follow-up of 7.6 years, showed a 12% reduction in prostate cancer-specific mortality in patients with the addition of radiation therapy (Lancet 2009;373:301-8). Updated results, now after median follow-up of 10.7 years, showed the 10-year cumulative prostate cancer-specific mortality was more than halved by the addition of radiation therapy, from 19% to just 8%, reported to Dr. Fosså, who disclosed no relevant conflicts of interests related to the research.


www.cancernetwork.com

"In these patients the combination of radiotherapy and hormones may be considered as a standard curative treatment option and patients should be informed about this," said Sophie Dorothea Fosså, MD, a professor in the department of oncology at Oslo University Hospital in Norway, at the 2014 ASCO Genitourinary Cancers Symposium.
This updated data showed that at 10 years, cumulative prostate-cancer-specific mortality was 8.3% in patients assigned combination treatment compared with 18.9% in the anti-androgen alone arm; at 15 years, it was 12.4% compared with 30.7% in the anti-androgen alone arm. In 2009, the Scandinavian Prostate Cancer Group presented results from this study showing a 12% reduction of prostate-cancer-specific mortality in patients on combined treatment after a median follow-up of 7.6 years. In these updated results, Fosså provided the 10-year and 15-year prostate-cancer-specific survival after a median observation of 10.7 years. Between 1996 and 2002, Fosså and colleagues enrolled 875 patients aged younger than 75 years from Norway, Sweden, and Denmark. All patients received 3 months of total androgen blockade and were then randomly assigned to endocrine treatment with the anti-androgen flutamide alone (n = 439) or combined with radiotherapy (n = 436). Looking at the final study results, patients assigned to combined treatment had an almost 11% reduction in absolute risk for prostate-cancer-specific mortality at 10 years, and an 18% reduction at 15 years. Specifically, there were 118 prostate-cancer-specific deaths in the anti-androgen alone arm compared with 45 in the combination arm. "Of course the difference was less for the overall mortality though still significant," Fosså said. Patients experienced long-term adverse effects concerning the urinary, bowel, and sexual dimensions, Fosså said.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory